US FDA revokes emergency use authorization of hydroxychloroquine for treatment of COVID-19

Image from Pixabay

The results of our study, published in JAMA Pediatrics, was used to support the US FDA’s decision to revoke emergency use authorization of hydroxychloroquine for treatment of COVID-19. Our model-based analysis demonstrated that hydroxychloroquine concentrations in lung tissue may be too low to elicit an antiviral effect - raising concerns about use of hydroxychloroquine for treatment of COVID-19. This work epitomizes the impact that pharmacokinetic modeling and simulation can have on clinical care. The FDA communication can be found here.